Advertisement

Topics

Latest "Aimmune Therapeutics" News Stories

10:51 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Aimmune Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Aimmune Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics for you to read. Along with our medical data and news we also list Aimmune Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Companies for you to search.

Showing "Aimmune Therapeutics" News Articles 1–25 of 7,800+

Extremely Relevant

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million Read more...


Jayson Dallas Leaves Ultragenyx for CEO Post at Aimmune

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: RARE) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an […]

Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy

BRISBANE, Calif. & ORLANDO, Fla.--(BUSINESS WIRE)--Mar. 4, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, announced that the results of its...


BRIEF — Aimmune trading higher on full PALISADE publication

US biotech Aimmune Therapeutics has published full results from its 554-patient Phase III PALISADE trial…

Aimmune expects FDA decision on peanut allergy therapy in August 2019

Aimmune Therapeutics anticipates an FDA advisory committee meeting for the approval of its lead oral immunotherapy candidate AR101 evaluated to treat peanut allergies,...Read More... The post Aimmune expects FDA decision on peanut allergy therapy in August 2019 appeared first on Pharmaceutical Technology.

Relevant

Aimmune to file peanut allergy treatment by year-end

Biotech company Aimmune has announced plans to file its potential peanut allergy treatment at the end of the year following its major phase 3 trial success. Aimmune saw its shares surge last month after the positive topline results from its PALISA...

Public offering nets $190mm for Aimmune

Aimmune Therapeutics Inc. (food allergy immunotherapies) netted $190mm through a public offering of 6.3mm common shares (incl...

Aimmune Therapeutics: Insider Buying Alert

Aimmune Therapeutics (AIMT) Investor Presentation - Slideshow

Reader Inquiry: How Has The Thesis Changed For Aimmune Therapeutics?

Aimmune Therapeutics: Special Situation Biotech Opportunity

Aimmune Therapeutics to Participate in Four Upcoming Investor Conferences in May and June

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in May and June: Event: Bank of America Merrill Lynch Healthcare ConferenceDate: May 16, 2018P...

Aimmune Therapeutics (AIMT) Presents At 38th Nasdaq Investor Conference - Slideshow

Aimmune Therapeutics to Participate in Four Investor Conferences in March

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor conferences in March: Event: 30th Annual ROTH ConferenceDate: Monday, March 12, 2018Presentation Time: 3:3...

Aimmune Therapeutics: An Interesting Business and Charts to Watch

Click to view a price quote on AIMT.

Aimmune Therapeutics to Present at Three Investor Conferences in September

Wells Fargo Healthcare Conference, September 5 Baird Global Healthcare Conference, September 6 Bank of America Merrill Lynch Global Healthcare Conference, September 12 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today ...

Your Daily Pharma Scoop: Aimmune Data, Onconova Shares Get A Boost, G1 Therapeutics' Positive Data

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the company’s President and CEO at the 2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15 at 1:55 p.m. Eastern Ti...

Aimmune Therapeutics Announces Data on Terminology Used with Oral Immunotherapy Were Presented ...

— U.S. Allergists Preferred “Tolerated Dose” as the Most Clinically Relevant Term to Communicate Desensitization Levels to Oral Immunotherapy Patients — Read more...

Aimmune Therapeutics Announces New Clinical Data on AR101 for Peanut Allergy at the 2018 EAACI Congress

New analyses including adults enrolled in the Phase 3 PALISADE trial of AR101 show efficacy across the entire intent-to-treat population of peanut-allergic patients ages 4-55 New immunologic subset analyses show that AR101 treatment was linked to depletion of peanut-specific TH2A cells believed to drive the allergic response...

Aimmune Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results

Company began 2018 with approximately $182 Million in cash and investments Pro-forma year-end 2017 cash and investments of approximately $372 Million, including net proceeds from the recently completed public offering Announced over-enrollment in the ARTEMIS Phase 3 trial Additional AR101 c...

Aimmune Therapeutics Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the underwriters of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share have exercised in full their option t...

Here, Take Another Hit Of This, Then Sell Some More Aimmune

Aimmune: Societal Benefits

Aimmune And DBV Technologies: A Comparison


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks